HOXB13 and other high penetrant genes for prostate cancer

被引:11
|
作者
Pilie, Patrick G. [1 ]
Giri, Veda N. [2 ]
Cooney, Kathleen A. [3 ,4 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Thomas Jefferson Univ, Dept Med Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
关键词
GENOME-WIDE SCAN; SUSCEPTIBILITY GENES; INTERNATIONAL CONSORTIUM; GERMLINE MUTATION; RISK; LINKAGE; MEN; FAMILIES; GENETICS; BRCA1;
D O I
10.4103/1008-682X.175785
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Cancer initiation and progression is the result of an accumulation of mutations in key tumor suppressor genes, mismatch repair genes, or oncogenes, which impact cancer cell growth, death, and differentiation. Mutations occurring in cancer tissue are termed somatic; whereas, heritable mutations that may be passed onto subsequent generations occur in germline DNA. It is these germline mutations that can lead to cancer family syndromes whereby family members carrying a deleterious germline mutation have an increased susceptibility to certain cancer phenotypes. Common features of hereditary cancer syndromes include early age-of-onset, multiple affected generations, rare tumor types, and/or multiple primary malignancies. Approximately, 5%-10% of all common cancers, including prostate cancer, have a hereditary component and are attributable to highly penetrant germline mutations.1 Across all cancer types, known cancer susceptibility syndromes number >100; however, it is important to note that mutations in high-penetrance genes explain only a fraction of heritable cancers.2 Well-known examples of hereditary cancer syndromes include Lynch (HNPCC), Cowden (PHTS), Li-Fraumeni, and Hereditary Breast and Ovarian Cancer (HBOC) syndromes, which are attributable to mutations in mismatch repair genes, PTEN, p53, and BRCA1/2, respectively.
引用
收藏
页码:530 / 532
页数:3
相关论文
共 50 条
  • [1] HOXB13 and prostate cancer
    Kyle Vogan
    [J]. Nature Genetics, 2012, 44 (3) : 241 - 241
  • [2] HOXB13 expression in metastatic prostate cancer
    Valeria Barresi
    Antonio Ieni
    Luca Reggiani Bonetti
    Giovanni Tuccari
    [J]. Virchows Archiv, 2016, 469 : 119 - 120
  • [3] HOXB13 expression in metastatic prostate cancer
    Justine Varinot
    Eva Comperat
    [J]. Virchows Archiv, 2016, 469 : 121 - 121
  • [4] HOXB13 mutations and prostate cancer in Poland
    Wojciech Kluźniak
    Dominika Wokołorczyk
    Jan Lubiński
    Cezary Cybulski
    [J]. Hereditary Cancer in Clinical Practice, 10 (Suppl 4)
  • [5] HOXB13 expression in metastatic prostate cancer
    Barresi, Valeria
    Ieni, Antonio
    Bonetti, Luca Reggiani
    Tuccari, Giovanni
    [J]. VIRCHOWS ARCHIV, 2016, 469 (01) : 119 - 120
  • [6] HOXB13 mutations and prostate cancer risk
    Cooney, Kathleen A.
    Beebe-Dimmer, Jennifer L.
    [J]. BJU INTERNATIONAL, 2016, 118 (04) : 496 - 497
  • [7] HOXB13 IS A PROSTATE CANCER SUSCEPTIBILITY GENE
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (02) : 105 - 105
  • [8] ALTERED HOXB13 FUNCTION IN HUMAN PROSTATE CANCER
    Chen, Shuangling
    Johng, Dorhyun
    Ewing, Charles
    Isaacs, William
    [J]. JOURNAL OF UROLOGY, 2014, 191 (04): : E323 - E324
  • [9] HOXB13 regulates androgen receptor expression in prostate cancer
    Chen, Shuangling
    Isaacs, William B.
    [J]. CANCER RESEARCH, 2013, 73
  • [10] Synonymous Polymorphisms in HOXB13 as a Protective Factor for Prostate Cancer
    Albitar, Ferras
    Diep, Kevin
    Ma, Wanlong
    Albitar, Maher
    [J]. JOURNAL OF CANCER, 2015, 6 (05): : 409 - 411